AI in Clinical Trials Faces New Regulatory Scrutiny Over Data Rights
Healthcare organizations and AI contractors are navigating complex legal frameworks as artificial intelligence becomes more prevalent in clinical trials, according to a new analysis by Clinical Leader. The article emphasizes the need for clear data rights agreements and regulatory compliance under U.S. Food and Drug Administration (FDA) guidelines when implementing AI systems in medical research.
The piece outlines key considerations for contracts involving AI in clinical trials, including data ownership, privacy protections, and adherence to 21 CFR Part 11 electronic record standards. Special attention is given to the FDA’s evolving requirements for AI/ML-based software as medical devices, which impact how trial data is collected, analyzed, and shared.
“Parties must explicitly define data rights in contracts to avoid disputes over intellectual property and patient information,” the article states. It also warns that failure to account for regulatory changes could delay trial approvals or result in enforcement actions.
The analysis comes as the FDA intensifies oversight of AI in healthcare, with 2023 seeing record numbers of AI-related submissions for medical device approvals. Legal experts consulted in the article recommend multidisciplinary teams—including AI developers, compliance officers, and contract specialists—to navigate these challenges.
